Corcept Therapeutics Inc (CORT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Corcept Therapeutics Inc (CORT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10063
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Corcept Therapeutics Inc (Corcept) is a research focused pharmaceutical company which discovers, develops and commercializes innovative therapeutics in the areas of psychiatric and metabolic diseases. The company focuses on developing drugs for the treatment of severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Corcept’s lead product candidate Korlym (mifepristone) is the first drug candidate to be approved for the treatment of patients with Cushing’s syndrome. Other products in the pipeline include mifepristone for psychotic depression; CORT 108297 and other GR antagonists that help in the prevention of antipsychotic-induced weight gain mitigation. Corcept is headquartered in Menlo Park, California, the US.

Corcept Therapeutics Inc (CORT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Corcept Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Corcept Therapeutics Enters into Agreement with Quotient Clinical 11
Corcept Therapeutics Enters into Agreement with Quotient Clinical for CORT122928 12
Corcept Therapeutics Enters into Agreement with Chiltern for CORT125134 13
Corcept Therapeutics Enters into Agreement with Quotient Clinical for CORT125134 14
Licensing Agreements 15
Corcept Therapeutics Enters into Licensing Agreement with University of Chicago 15
Equity Offering 16
Corcept Therapeutics Raises USD17.2 Million in Private Placement of Shares upon Exercise of Warrants 16
Corcept Therapeutics Completes Public Offering Of Common Stock For US$46.4 Million 17
Corcept Therapeutics Completes Private Placement Of Shares For US$12.4 Million Upon Exercise Of Warrants 18
Asset Transactions 19
Pharmakon Advisors Acquires Royalties Of Korlym From Corcept Therapeutics For Up To US$45 Million 19
Corcept Therapeutics Inc – Key Competitors 20
Corcept Therapeutics Inc – Key Employees 21
Corcept Therapeutics Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Nov 01, 2018: Corcept Therapeutics announces third quarter 2018 financial results and provides corporate update 23
Aug 09, 2018: Corcept Therapeutics announces second quarter 2018 financial results and stock repurchase program; Provides clinical update 25
May 08, 2018: Corcept Therapeutics Announces First Quarter 2018 Financial results and Provides Corporate Update 28
Feb 22, 2018: Corcept Therapeutics Announces 2017 Financial Results and Positive Interim Results of Relacorilant Phase 2 Trial 29
Feb 01, 2018: Corcept Therapeutics Announces Fourth Quarter and Full-Year 2017 Preliminary Selected Financial Results; Provides 2018 Revenue Guidance 31
Nov 02, 2017: Corcept Therapeutics Announces Third Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update 32
Aug 01, 2017: Corcept Therapeutics Announces Second Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update 33
May 01, 2017: Corcept Therapeutics Announces First Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update 34
Mar 06, 2017: Corcept Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results; Increases 2017 Revenue Guidance 35
Jan 30, 2017: Corcept Therapeutics Announces Preliminary Fourth Quarter and Full-Year 2016 Financial Results 36
Jan 30, 2017: Corcept Therapeutics Annnounces Preliminary Fourth Quarter and Full-Year 2016 Financial Results and Corporate Update; Provides 2017 Revenue Guidance 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Corcept Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Corcept Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Corcept Therapeutics Enters into Agreement with Quotient Clinical 11
Corcept Therapeutics Enters into Agreement with Quotient Clinical for CORT122928 12
Corcept Therapeutics Enters into Agreement with Chiltern for CORT125134 13
Corcept Therapeutics Enters into Agreement with Quotient Clinical for CORT125134 14
Corcept Therapeutics Enters into Licensing Agreement with University of Chicago 15
Corcept Therapeutics Raises USD17.2 Million in Private Placement of Shares upon Exercise of Warrants 16
Corcept Therapeutics Completes Public Offering Of Common Stock For US$46.4 Million 17
Corcept Therapeutics Completes Private Placement Of Shares For US$12.4 Million Upon Exercise Of Warrants 18
Pharmakon Advisors Acquires Royalties Of Korlym From Corcept Therapeutics For Up To US$45 Million 19
Corcept Therapeutics Inc, Key Competitors 20
Corcept Therapeutics Inc, Key Employees 21
Corcept Therapeutics Inc, Subsidiaries 22

List of Figures
Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Corcept Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Corcept Therapeutics Inc (CORT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Greatcell Solar Ltd (GSL)-エネルギー分野:企業M&A・提携分析
    Summary Greatcell Solar Ltd (Greatcell Solar), formerly Dyesol Limited, is a renewable energy company that develops and commercializes Perovskite Solar Cells (PSC) or solid-state dye solar cell (DSC), the third generation photovoltaic technology. The company develops a range of PSC chemicals, compon …
  • Tenaska Inc:電力:M&Aディール及び事業提携情報
    Summary Tenaska Inc (Tenaska) is an independent power development and energy marketing company. It develops, designs, finances, and manages and operates power plants. The company purchases and sells natural gas, electric capacity, energy, and renewable energy products; acquires, manages, and optimiz …
  • Tribal Group Plc (TRB):企業の財務・戦略的SWOT分析
    Tribal Group Plc (TRB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Texas Children’s Hospital:企業の戦略的SWOT分析
    Texas Children's Hospital - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • ATI Physical Therapy-製薬・医療分野:企業M&A・提携分析
    Summary ATI Physical Therapy (ATI) is a healthcare service provider that offers therapy services. The center offers therapy services such as physical therapy, workers' comp rehab, sports therapy, hand therapy, women's health, specialty therapies, home health and complimentary injury screening servic …
  • Santen Pharmaceutical Co Ltd (4536):製薬・医療:M&Aディール及び事業提携情報
    Summary Santen Pharmaceutical Co Ltd (Santen) focuses on the research, development, manufacture and marketing of pharmaceutical products and medical devices. Its product portfolio includes prescription ophthalmic products for bacterial conjunctivitis, glaucoma, dry eye, Inflammation and others; OTC …
  • Geron Corp (GERN):企業の財務・戦略的SWOT分析
    Geron Corp (GERN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Westgold Resources Ltd (WGX):企業の財務・戦略的SWOT分析
    Westgold Resources Ltd (WGX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • NanoString Technologies Inc (NSTG):企業の財務・戦略的SWOT分析
    Summary NanoString Technologies Inc (NanoString) is a developer of life science tools for translational research and molecular diagnostics. The company's products include sprint profiler, Dx analysis system with flex, nCounter MAX analysis system, protein assays, solid tumor assays, gene fusion pane …
  • Swissgrid AG:企業の戦略的SWOT分析
    Swissgrid AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Range Resources Ltd (RRS):石油・ガス:M&Aディール及び事業提携情報
    Summary Range Resources Ltd (Range Resources) is an independent upstream oil and gas company. It explores, develops and produces oil and gas in Georgia, Guatemala and Trinidad. The company works on both onshore and offshore production and its onshore projects are operational through water injection. …
  • Bush Industries Inc:企業の戦略・SWOT・財務情報
    Bush Industries Inc - Strategy, SWOT and Corporate Finance Report Summary Bush Industries Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Exxaro Resources Ltd:企業の戦略・SWOT・財務分析
    Exxaro Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Exxaro Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Huntsman Corp (HUN):企業の財務・戦略的SWOT分析
    Huntsman Corp (HUN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • The Binding Site Group Ltd:企業の製品パイプライン分析2018
    Summary The Binding Site Group Ltd (Binding Site) is a clinical diagnostic tools supplier that concentrates on research, development, manufacturing and distribution of immunodiagnostic assays. The company provides product portfolio such as antibodies, antigens, bulk antisera, assays for plasma prote …
  • Ecobank Transnational Inc:企業の戦略・SWOT・財務情報
    Ecobank Transnational Inc - Strategy, SWOT and Corporate Finance Report Summary Ecobank Transnational Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Coeur Mining Inc:企業の戦略・SWOT・財務分析
    Coeur Mining Inc - Strategy, SWOT and Corporate Finance Report Summary Coeur Mining Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Trident Exploration Corp:石油・ガス:M&Aディール及び事業提携情報
    Summary Trident Exploration Corp (Trident) is an independent natural gas production company. The company operates in the business of exploration and exploiting of unconventional natural gas resources in the Western Canadian Sedimentary Basin. It operates in the production of coal bed methane. Triden …
  • Small Industries Development Bank of India:企業のM&A・事業提携・投資動向
    Small Industries Development Bank of India - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Small Industries Development Bank of India Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detai …
  • Filtration Group Corp:企業の戦略的SWOT分析
    Filtration Group Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆